PHILIPPE P. ROUX, Ph.D.
- Principal Investigator, Laboratory of Cell Signalling and Proteomics, Institute for Research in Immunology and Cancer
- Assistant Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal
AWARDS & HONORS
- Career Development Award, Human Frontier Science Program, 2007-
- Canada Research Chair in Signal Transduction and Proteomics, 2006-
- Fellowship, Human Frontier Science Program, 2003-2006
- Fellowship, Canadian Institutes of Health Research, 2002-2003
- Dean’s Honour List for Doctoral Thesis, McGill University, 2002
- Doctoral Award, Canadian Institutes of Health Research, 1999-2002
- Doctoral Award, Neuroscience Canada Foundation, 1998-1999
- Doctoral Award, Jean Timmons Costello Foundation, 1997-1998
- Studentship, Quebec Social Services Council, 1995-1997
- Merit Award, National Toxicology Council of Canada, 1995
TRAINING
- Postdoctoral training with John Blenis, Department of Cell Biology, Harvard Medical School, 2002-2006
- Ph.D. in Neurological Sciences with Phil Barker and Tim Kennedy, Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, 2002
- M.Sc. in Microbiology and Immunology with Caroline Alfieri and Jerome Tanner, Department of Microbiology and Immunology, University of Montreal, 1997
RESEARCH SUPPORT
- Canada Foundation for Innovation
- Canadian Institutes of Health Research
- Canadian Cancer Society Research Institute
- Human Frontier Science Program
Philippe Roux is a principal investigator at the Institute for Research in Immunology and Cancer (IRIC) and a Canada Research Chair in Cell Signalling and Proteomics since 2006. He is an Assistant Professor with the Department of Pathology and Cell Biology in the Faculty of Medicine of the University of Montreal.
When Dr. Roux began his doctoral studies at the Montreal Neurological Institute of McGill University in 1997, he was particularly interested in the signal transduction pathways implicated in the regulation of neuronal survival and apoptosis. He chose to investigate the signalling mechanisms initiated by the atypical growth factor receptor p75NTR and found that this protein regulates both cell faiths depending on the cellular context. Dr. Roux also used mouse and rat models of excitatory seizures to assess the role of p75NTR in vivo. His studies demonstrated a tight correlation between induced p75NTR expression and neuronal apoptosis, suggesting that this receptor regulates neuronal cell fate in response to trauma within the central nervous system.
In a quest for thorough training in signal transduction, Philippe Roux joined the group of Dr. John Blenis in the Department of Cell Biology of Harvard Medical School in Boston. He was funded by the Canadian Institutes of Health Research and was awarded the prestigious Long-Term Fellowship from the Human Frontier Science Program Organization (2003-2006) to accomplish this phase of his career. His work there focused on the MAP kinase signalling pathway and the mechanisms by which mitogenic cues promote cell growth and proliferation. While studying the evolutionarily conserved RSK family of protein kinases, Dr Roux made important discoveries on the regulation these enzymes as well as their role in cell growth control through the identification of novel RSK substrates.
After more than four years away from Quebec, Dr. Roux returned in 2006 to begin work as a principal investigator at IRIC. His research team seeks to understand the mechanisms by which various oncogenes regulate cell growth and proliferation. Using cell biological and biochemical assays, as well cutting edge proteomics methods, Dr. Roux aims to identify novel phospho-regulatory mechanisms and thereby identify novel therapeutic targets for the treatment of cancer.
SELECTED PUBLICATIONS
Tcherkezian J, Brittis PA, Thomas F, Roux PP, Flanagan JG (2010) Transmembrane Receptor DCC Associates with Protein Synthesis Machinery and Regulates Translation.
Cell. Apr 28. [Epub ahead of print]
Julien LA, Carriere A, Moreau J, Roux PP. (2009) mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling. Mol Cell Biol. 30(4):908-21.
Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA, Carriere A, Roux PP, Ballif BA, Fingar DC. (2009) Regulation of mTOR complex 1 (mTORC1) by raptor S863 and multi-site phosphorylation. Biol Chem. 285(1):80-94.
Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 105:17414-9
Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol. 18:1269-77
Carriere A, Ray H, Blenis J, Roux PP (2008) The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci. 13:4258-75
Roux PP (2007) Rsk4. UCSD-Nature Molecule Pages (doi:10.1038/mp.a002102.01)
Julien LA and Roux PP (2007) Rsk3. UCSD-Nature Molecule Pages (doi:10.1038/mp.a002101.01)
Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282:14056-14064
Roux PP (2007) Rsk1. UCSD-Nature Molecule Pages (doi:10.1038/mp.a002099.01)
Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. Embo J 25:2781-2791
Choo AY, Roux PP, Blenis J (2006) Mind the GAP: Wnt steps onto the mTORC1 train. Cell 126:834-836
Ballif BA*, Roux PP*, Gerber SA, MacKeigan JP, Blenis J, Gygi SP (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A 102:667-672 * co-first authors
Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J (2005) The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol 15:1762-1767
Roux PP and Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320-344
Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101:13489-13494
Bouchard JF, Moore SW, Tritsch NX, Roux PP, Shekarabi M, Barker PA, Kennedy TE (2004) Protein kinase A activation promotes plasma membrane insertion of DCC from an intracellular pool: A novel mechanism regulating commissural axon extension. J Neurosci 24:3040-3050
Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259-1268
Roux PP, Richards SA, Blenis J (2003) Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23:4796-4804
Top
<< Back to Investigators
